sodium bicarbonate; tartaric acid
Drug data last refreshed 3h ago · AI intelligence enriched Yesterday
BAROS is an oral effervescent granule combining sodium bicarbonate and tartaric acid, approved in 1985 for symptomatic relief of acid indigestion and heartburn. The formulation works through acid-base neutralization, providing rapid relief when dissolved in water. This is a mature, over-the-counter antacid product with a simple mechanism suitable for gastric pH management.
Product approaching loss of exclusivity with moderate competitive pressure (30), suggesting defensive marketing and cost-management focus rather than growth-stage resource investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Impact of Barostimulation on Hemodynamics in Adults With Heart Failure
Symptomatic CRT Patients: Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence
Real-World Experience - Barostim™ Advancing the Level of Clinical Evidence (REBALANCE Registry)
BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BAROS offers limited career growth and minimal linked job opportunities, reflecting its mature market status and approaching loss of exclusivity. Roles tend to focus on operational efficiency and cost management rather than innovation or market expansion.